AZD9056 hydrochloride
Based on 6 publication(s) in Google Scholar
AZD9056 hydrochloride is a selective orally active inhibitor of P2X7 which plays a significant role in inflammation and pain-causing diseases.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 98.18%
- CAS No.: 345303-91-5
- 화학식: C24H36Cl2N2O2
- 분자량:455.46
-
보관:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- Protocol
- 순도&문서
- References
-
Help & FAQs
-
HY-50697
A-740003P2X Receptor Antagonist -
HY-123857
JNJ-55308942P2X7 Antagonist -
HY-17593
SolithromycinAntibiotic -
HY-15469
GW791343 dihydrochlorideHuman P2X7 Receptor Negative Allosteric Modulator -
HY-15488A
A 438079 hydrochlorideP2X7 Receptor Antagonist -
HY-15488
A 438079P2X Receptor Antagonist -
HY-101588
GefapixantP2X3 Antagonist -
HY-15487
CE-224535P2X Receptor Antagonist -
HY-101418
JNJ-47965567P2X7 Antagonist -
HY-13954
A 839977P2X7 Antagonist -
HY-19888
GSK-1482160P2X7 Modulator -
HY-117508
JNJ-54175446P2X7 Antagonist
Publications Citing Use of MedChemExpress (MCE) AZD9056 hydrochloride
More- Adv Sci (Weinh). 2025 Nov 6:e14842. [Abstract]
- ACS Appl Mater Interfaces. 2025 Feb 5;17(5):7521-7538. [Abstract]
- Front Immunol. 2021 Jan 8;11:602016. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2024 Jan;1870(1):166895. [Abstract]
- J Pharmacol Sci. 2020 Sep;144(1):43-51. [Abstract]
- Biochem Genet. 2025 Dec 6. [Abstract]
All P2X Receptor Isoforms
More
Biological Activity
제품 설명
IC50 & Target
|
P2X7 Receptor |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
0.23 nM
Compound: 2; AZD9056
|
Antagonist activity at human P2X7 receptor expressed in HEK293 cells assessed as inhibition of BzATP-induced EtBr uptake measured after 2 hrs by fluorescence analysis
Antagonist activity at human P2X7 receptor expressed in HEK293 cells assessed as inhibition of BzATP-induced EtBr uptake measured after 2 hrs by fluorescence analysis
|
[PMID: 27427902] |
| J774.A1 | IC50 |
11.8 μM
Compound: 5, AZD9056
|
Antagonist activity at P2X7 receptor in LPS-primed mouse J774.A1 cells assessed as inhibition of ATP-induced IL-1beta release after 30 mins by ELISA
Antagonist activity at P2X7 receptor in LPS-primed mouse J774.A1 cells assessed as inhibition of ATP-induced IL-1beta release after 30 mins by ELISA
|
[PMID: 25597334] |
| MDA-MB-231 | IC50 |
8.699 μM
Compound: 2; AZD9056
|
Antiinvasive activity against human MDA-MB-231 cells measured after 48 hrs by transwell invasion assay
Antiinvasive activity against human MDA-MB-231 cells measured after 48 hrs by transwell invasion assay
|
[PMID: 27427902] |
| THP-1 | IC50 |
0.06 nM
Compound: 2; AZD9056
|
Antagonist activity at human P2X7 receptor in LPS/IFN-gamma-differentiated human THP-1 cells assessed as suppression of BzATP-stimulated IL-1beta release per-incubated for 30 mins before BzATP addition and measured after 30 mins by ELISA
Antagonist activity at human P2X7 receptor in LPS/IFN-gamma-differentiated human THP-1 cells assessed as suppression of BzATP-stimulated IL-1beta release per-incubated for 30 mins before BzATP addition and measured after 30 mins by ELISA
|
[PMID: 27427902] |
In Vitro
The antagonist AZD9056 blocks P2X7 receptors with an IC50 of 11.2 nM in HEK-hP2X7 cell line, indicating a high selectivity of the antagonist for the P2X7 receptor. The P2X7-receptor antagonist AZD9056 has a clear inhibitory effect (IC50=1-3 μM) in mouse microglia BV2 cells[1]. AZD9056 is an inhibitor of BCRP and weakly inhibits BCRP-mediated transport of methotrexate (IC50=92 μM)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 345303-91-5
-
Appearance Solid
-
분자량 455.46
-
화학식 C24H36Cl2N2O2
-
Color White to off-white
-
SMILES
O=C(C1=CC(CCCNCCCO)=CC=C1Cl)NCC2(C[C@H](C3)C4)C[C@H]4C[C@H]3C2.Cl
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, sealed storage, away from moisture
* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
2025 Nov 6:e14842. PMID: 41195564 -
ACS Appl Mater Interfaces
The P2X7-Mediated Mitochondrial ROS as an Emerging Core Target of Tuftsin Nanoparticles in Severe Acute Pancreatitis Therapy via Regulating Mitophagy. [Abstract]2025 Feb 5;17(5):7521-7538. PMID: 39854589 -
Front Immunol
Stimulation of Vibratory Urticaria-Associated Adhesion-GPCR, EMR2/ADGRE2, Triggers the NLRP3 Inflammasome Activation Signal in Human Monocytes. [Abstract]2021 Jan 8;11:602016. PMID: 33488598 -
Biochim Biophys Acta Mol Basis Dis
Extracellular ATP (eATP) inhibits the progression of endometriosis and enhances the immune function of macrophages. [Abstract]2024 Jan;1870(1):166895. PMID: 37748566 -
J Pharmacol Sci
2020 Sep;144(1):43-51. PMID: 32653340 -
Biochem Genet
Network Pharmacology and Experimental Validation Reveal Wu Miao Pill's Therapeutic Effects on Acute Gouty Arthritis Through P2X7R Regulation. [Abstract]2025 Dec 6. PMID: 41351812
용액&용해도
In Vitro:
DMSO : 50 mg/mL (109.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 1.67 mg/mL (3.67 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.49 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.49 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (275 KB)
-
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
-
Handling Instructions (2659 KB)
References
[1]. Seeland S, et al. ATP-induced cellular stress and mitochondrial toxicity in cells expressing purinergic P2X7 receptor. Pharmacol Res Perspect. 2015 Mar;3(2):e00123. [Content Brief]
[2]. Elsby R, et al. In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate. Eur J Pharm Sci. 2011 May 18;43(1-2):41-9. [Content Brief]
[3]. Hu H, et al. Blocking of the P2X7 receptor inhibits the activation of the MMP-13 and NF-κB pathways in the cartilage tissue of rats with osteoarthritis. Int J Mol Med. 2016 Dec;38(6):1922-1932. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.1956 mL | 10.9779 mL | 21.9558 mL | 54.8896 mL |
| DMSO | 5 mM | 0.4391 mL | 2.1956 mL | 4.3912 mL | 10.9779 mL |
| 10 mM | 0.2196 mL | 1.0978 mL | 2.1956 mL | 5.4890 mL | |
| 15 mM | 0.1464 mL | 0.7319 mL | 1.4637 mL | 3.6593 mL | |
| 20 mM | 0.1098 mL | 0.5489 mL | 1.0978 mL | 2.7445 mL | |
| 25 mM | 0.0878 mL | 0.4391 mL | 0.8782 mL | 2.1956 mL | |
| 30 mM | 0.0732 mL | 0.3659 mL | 0.7319 mL | 1.8297 mL | |
| 40 mM | 0.0549 mL | 0.2744 mL | 0.5489 mL | 1.3722 mL | |
| 50 mM | 0.0439 mL | 0.2196 mL | 0.4391 mL | 1.0978 mL | |
| 60 mM | 0.0366 mL | 0.1830 mL | 0.3659 mL | 0.9148 mL | |
| 80 mM | 0.0274 mL | 0.1372 mL | 0.2744 mL | 0.6861 mL | |
| 100 mM | 0.0220 mL | 0.1098 mL | 0.2196 mL | 0.5489 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
AZD9056 hydrochloride Related Classifications
HY-19427A Related Classifications
Powered by Bioz